Rekabi Mahsa, Sadati Elham, Mirzaei Jamal, Pourdowlat Guitti, Velayati Ali Akbar, Honarpisheh Parisa
Allergy and Immunology Department, Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD) Shahid Beheshti University of Medical Sciences Tehran Iran.
Infectious Disease Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
JEADV Clin Pract. 2022 Jun 29. doi: 10.1002/jvc2.40.
After coronavirus disease 2019 (COVID-19) became widespread around the world, several vaccines have been developed with variable efficacy and potency and based on different platforms to control the pandemic. One of these vaccines is Sinopharm (BBIBP-CorV), which is an inactivated virus that was released by Sinopharm's Beijing institute in the summer of 2020. The most commonly reported side effects of the Sinopharm vaccine have included pain at the injection site, muscle pain, headache and fatigue. Dermatological reactions are also reported as less common and were mainly local injection site reactions. Fixed drug eruption (FDE) is a rare and unusual adverse effect and accounts for less than 1% of all severe acute respiratory syndrome coronavirus 2 vaccine-related cutaneous manifestations. FDE has not been reported following the COVID-19 inactivated vaccine. Here, we describe a rare case of FDE following the administration of the first shot of the Sinopharm vaccine.
2019年冠状病毒病（COVID-19）在全球广泛传播后，人们基于不同平台研发了几种效力和效果各异的疫苗来控制这一疫情。其中一种疫苗是国药集团（BBIBP-CorV），它是一种灭活病毒疫苗，由国药集团北京生物制品研究所在2020年夏季推出。国药集团疫苗最常报告的副作用包括注射部位疼痛、肌肉疼痛、头痛和疲劳。皮肤反应报告较少见，主要是局部注射部位反应。固定型药疹（FDE）是一种罕见且不寻常的不良反应，在所有严重急性呼吸综合征冠状病毒2疫苗相关皮肤表现中占比不到1%。COVID-19灭活疫苗接种后尚未有FDE的报告。在此，我们描述一例接种国药集团疫苗第一针后发生FDE的罕见病例。
